下肢血运重建后迟发出血事件的发生率与意义
该回顾性研究纳入1932例因晚期外周动脉疾病行下肢血运重建的患者,27.4%在4.3年内发生出血事件(53%为大出血)。出血与再干预、大截肢、心肌梗死、卒中和死亡风险升高相关,且40%的患者发生复发性出血,并显著影响抗血栓药物处方。
要点
- 下肢血运重建后27.4%发生迟发出血,53%为大出血,胃肠道最常见(47%)。
- 40%患者发生复发性出血,首次出血后15%出院时未用任何抗血栓治疗。
核心结论
- 晚期外周动脉疾病患者下肢血运重建后出血事件常见,并与更差的总体结局相关;复发性出血很可能发生并显著影响抗血栓药物处方。
研究设计与样本
- 单中心回顾性研究,纳入因外周动脉疾病行下肢血运重建的患者1932例,出血按国际血栓形成学会定义分为大出血和小出血,且仅记录血运重建30天围术期之外的出血事件。
主要发现
- 共1932例患者行下肢血运重建,529例(27.4%)在4.3年内发生出血事件,其中53%为大出血、47%为小出血。
- 出血事件最常见类型为胃肠道出血(47%),其次为与下肢血运重建无关的手术部位出血(13%),以及颅内出血。
- 48%的患者接受了输血;40%的首次出血患者发生至少一次复发性出血,平均每人2.9次出血事件。
- 首次出血后,15%的患者出院时未接受任何抗血栓治疗,分别有13%、16%和11%的患者停用阿司匹林、P2Y12抑制剂和抗凝治疗。
- 出血患者随访期间再干预51% vs 43%(P=0.002)、大截肢14% vs 7.1%(P<0.001)、心肌梗死33% vs 17%(P<0.001)、卒中9.5% vs 5.1%(P<0.001)、死亡48% vs 38%(P<0.001)。
关键数值与推荐
- 出血事件定义采用国际血栓形成学会定义,分为大出血和小出血,且仅纳入下肢血运重建30天围术期之后的出血事件。
- 出血组基线合并高血压93% vs 89%(P=0.005)、冠心病58% vs 53%(P=0.047)、慢性肾功能不全25% vs 16%(P<0.001)、终末期肾病12% vs 6.8%(P<0.001)、吸烟史84% vs 79%(P=0.007)、双联抗血小板治疗31% vs 25%(P=0.029)。
- 出血组首次下肢血运重建后发生围术期出血的比例为7.6% vs 5.2%(P=0.049)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As novel medications are used in various combinations to prevent thrombosis, few studies have focused on bleeding events after lower extremity revascularization (LER) in patients with peripheral artery disease (PAD). Moreover, the impact of bleeding events on long-term outcomes and the prescription of antithrombotic therapy is not well-reported. This study examines the incidence of bleeding events after LER and their significance in patients with advanced PAD. METHODS: A retrospective review of patients undergoing LER for PAD in a tertiary care center was performed. Bleeding was classified into major and minor based on the International Society of Thrombosis definitions and captured outside the 30-day perioperative period of LER. Characteristics and outcomes of patients who experienced bleeding events more than 30 days after initial LER were compared with patients who did not. RESULTS: A total of 1932 patients underwent LER, and 529 (27.4%) experienced a bleeding event (53% major, 47% minor) over 4.3 years. Patients who experienced a bleeding event were more likely to have hypertension (93% vs 89%; P = .005), coronary artery disease (58% vs 53%; P = .047), chronic renal insufficiency (25% vs 16%; P < .001), end-stage renal disease (12% vs 6.8%; P < .001), a history of smoking (84% vs 79%; P = .007), and be on dual antiplatelet therapy (31% vs 25%; P = .029) at baseline. Patients who experienced a bleeding event after 30 days were also more likely to have developed perioperative bleeding (7.6% vs 5.2%; P = .049) after the first LER. On follow-up, patients with bleeding were more likely to have reinterventions (51% vs 43%; P = .002), major amputation (14% vs 7.1%; P < .001), myocardial infarction (33% vs 17%; P < .001), stroke (9.5% vs 5.1%; P < .001), and mortality (48% vs 38%; P < .001). The most common type of bleeding was gastrointestinal (47%), followed by surgical site unrelated to LER (13%), and intracranial. Blood transfusion was used in 48% of patients. Moreover, 40% of patients with an initial bleeding episode had at least one recurrent bleeding episode, with a mean of 2.9 bleeding episodes per patient. After the first bleeding episode, 15% of patients were discharged without any antithrombotic therapy and 13%, 16%, and 11% had discontinuation of ASA, P2Y12 inhibitors, and anticoagulation respectively. CONCLUSIONS: Bleeding events are common after LER for advanced PAD and are associated with worse overall outcomes. Recurrent bleeding events are likely and significantly affect antithrombotic medication prescriptions.
引用
- Hundito A, Wells N, Tuttle M, et al. The incidence and significance of delayed bleeding events after lower extremity revascularization in patients with advanced peripheral arterial disease. J Vasc Surg. 2025. PMID: 40187383. doi:10.1016/j.jvs.2025.03.394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。